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The Potential Danger of Empiric Antimicrobial Therapy for Nosocomial SBP 
Dear Sirs 
Piano et al’s suggestion in their study of empiric treatment of nosocomial spontaneous bacterial 
peritonitis (SBP) that these antibiotics of last resort should become standard in areas with high multi 
drug-resistant bacteria is potentially dangerous.(1) We agree with the editorial that nosocomial SBP 
represents a worryingly evidence-free zone with few prospective studies and opinion based 
guidelines – in turn making this study capable of considerable impact for policy.(2)  One size definitely 
does not fit all, but we would go further to state that the challenge of antimicrobial resistance 
requires a more thoughtful approach, rather than automatic deployment of broad spectrum 
antibiotics.(3) Italy has high cephalosporin and carbapenem resistance rates, with some organisms 
exceeding 50% resistance and fluoroquinolone-based antibiotic prophylaxis may drive this.(4) 
Therefore it would be both incorrect and irresponsible to advocate such a combination in countries 
with lower resistance. 
This study relies on surrogate markers of infection and resolution with no difference in survival. 
Although a polymorphonuclear cell (PMNC) count >250 /mm3 demonstrated 100% sensitivity and 
89% specificity in culture positive SBP, Piano et al isolated bacteria in 51.6% patients in line with 
others.(3, 5) This was greater in the ceftazidime group (62.5% vs 40%). Patients with positive cultures 
have significantly worse outcomes and this confounder was not considered. Patients with a PMNC 
count >250/mm3 will be treated with antibiotics in many countries regardless of culture results; we 
could be treating half of these people unnecessarily. Greater attempts should be made to 
understand the characteristics of patients with negative ascitic culture and elevated PMNCs. In 
particular can antibiotics be stopped? 
The key finding is efficacy of first-line treatment independently predicted survival and it therefore 
follows that we must focus on delivering the correct antibiotics to the correct patients. We believe 
that adoption of their recommendations for empiric antibiotics will lead to further antibiotic 
pressure, both in terms of spectrum and treatment duration. Neither is necessary; many patients 
may not need antibiotics in the first place, and rapid de-escalation flowing from antibiotic sensitivity 
data should be the rule. There is no choice; to continue to deploy increasingly precious antibiotics 
without thought for alternative strategies will fail, and patients will die for lack of effective therapy. 
This paper’s value lies therefore in its potential to stimulate multi-centre studies and strategies to 
improve antibiotic use before we lose them altogether. 
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